Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction-Reference-Cited by-同舟云学术

Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction

Published:2020-08-01 Issue:8 Volume:5 Page:952
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Gencer Baris¹²,Mach François²,Murphy Sabina A.¹,De Ferrari Gaetano M.³,Huber Kurt⁴,Lewis Basil S.⁵,Ferreira Jorge⁶,Kurtz Christopher E.⁷,Wang Huei⁷,Honarpour Narimon⁷,Keech Anthony C.⁸,Sever Peter S.⁹,Pedersen Terje R.¹⁰,Sabatine Marc S.¹¹¹,Giugliano Robert P.¹

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

2. Cardiology Division, Geneva University Hospitals, Geneva, Switzerland

3. Division of Cardiology Città della Salute e della Scienza, Department of Medical Sciences, University of Torino, Turin, Italy

4. Department of Medicine, Cardiology and Intensive Care Medicine and Sigmund Freud University, Medical School, Vienna, Austria

5. Lady Davis Carmel Medical Center, Haifa, Israel

6. Hospital de Santa Cruz, Lisbon, Portugal

7. Amgen, Thousand Oaks, California

8. Sydney Medical School, National Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, Australia

9. National Heart and Lung Institute, Imperial College London, London, United Kingdom

10. Oslo University Hospital, Ulleval and Medical Faculty, University of Oslo, Oslo, Norway

11. Deputy Editor, JAMA Cardiology

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Link

https://jamanetwork.com/journals/jamacardiology/articlepdf/2766279/jamacardiology_gencer_2020_br_200003_1597695778.56445.pdf

Reference14 articles.

1. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.;Grundy;Circulation,2019

2. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.;Cannon;N Engl J Med,2004

3. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.;Schwartz;JAMA,2001

4. Ezetimibe added to statin therapy after acute coronary syndromes.;Cannon;N Engl J Med,2015

5. Clinical benefit of evolocumab by severity and extent of coronary artery disease: analysis from FOURIER.;Sabatine;Circulation,2018

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients Following Acute Coronary Syndromes: From Lipid Lowering and Plaque Stabilization to Improved Outcomes;Journal of Clinical Medicine;2024-08-25

2. Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives;Current Atherosclerosis Reports;2024-07-15

3. Proprotein convertase subtilisisn/kexin type 9 inhibitors: the earlier the better?;European Journal of Preventive Cardiology;2024-06-28

4. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition;European Journal of Clinical Investigation;2024-06-26

5. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression;Current Medical Research and Opinion;2024-06-11